Methods for diagnosis, prognosis and methods of treatment
AssigneeNodality, Inc.
InventorsAlessandra Cesano, Rachael Hawtin, Santosh Putta
Life of this patent
Estimating the term…
Abstract
The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations.
Claims28
A method of treating an individual suffering from acute myeloid leukemia (AML), wherein the individual is greater than 55 years old, comprising administering araC to the individual based on a decision to treat the individual, wherein the decision to treat the individual is based at least in part on the results of a test comprising:
- (i) contacting cells from a sample from the individual with one or more agents that induce apoptosis;
- and
- (ii) determining a level of apoptosis in the cells by a process that comprises determining, in single cells, a level of a first marker, wherein the first marker is a marker of apoptosis.
(canceled)
-16. (canceled)
-21. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A kit for determining whether or not to treat an individual greater than 55 years of age suffering from acute myeloid leukemia (AML) with a treatment comprising administering araC to the individual, comprising:
- (i) at least two agents that induce apoptosis, selected from the group consisting of etoposide, ara C, staruosporine, and daunorubicin;
- (ii) a detectable binding element for detecting a marker of apoptosis selected from the group consisting of pChk2, p-H2AX, Bcl-2, cytochrome c, c-caspase 3, c-caspase 8, and cPARP;
- (iii) at least two detectable binding elements that bind to cell surface markers;
- and
- (iv) instructions for use, wherein the instructions for use are physically included with the other elements of the kit or supplied separately for use with the kit by electronic or physical delivery to an end user of the kit.
-43. (canceled)
Dependencies are inferred from the claim text.